Wedge Industrial (000534) Q2 2026 earnings summary

Executive summary

• Revenue for H1 2026 reached ¥666.60 million, up 6.58% year-over-year; net profit attributable to shareholders was ¥125.38 million, up 5.00% year-over-year.

• Main businesses: microecological active bacteria products and high-temperature alloy R&D, production, and sales.

• Pharmaceutical segment maintained stable growth, with innovation in R&D and expansion of online sales channels.

• High-temperature alloy segment accelerated industrialization, achieved breakthroughs in domestic and international markets.

Financial highlights

• Operating income: ¥666.60 million (+6.58% YoY); net profit attributable to shareholders: ¥125.38 million (+5.00% YoY).

• Net profit excluding non-recurring items: ¥109.41 million (-0.79% YoY).

• Operating cash flow: -¥32.59 million (down from +¥6.21 million YoY).

• Total assets: ¥5.23 billion (+14.00% from year-end 2025); net assets: ¥1.87 billion (+16.63%).

• Basic EPS: ¥0.2510; diluted EPS: ¥0.2461.

• R&D investment: ¥130.71 million (+41.96% YoY).

Outlook and guidance

• Company will continue to focus on innovation, capacity expansion, and digital transformation.

• Plans to further develop both microecological and high-temperature alloy businesses, leveraging national policy support.